Microsomal triglyceride transfer protein (MTP) transfers lipids to apolipoprotein B (apoB) within the endoplasmic reticulum, a process that involves direct interactions between apoB and the large subunit of MTP. Recent studies with heterozygous MTP knockout mice have suggested that half-normal levels of MTP in the liver reduce apoB secretion. We hypothesized that reduced apoB secretion in the setting of half-normal MTP levels might be caused by a reduced MTP:apoB ratio in the endoplasmic reticulum, which would reduce the number of apoB-MTP interactions. If this hypothesis were true, half-normal levels of MTP might have little impact on lipoprotein secretion in the setting of halfnormal levels of apoB synthesis (since the ratio of MTP to apoB would not be abnormally low) and might cause an exaggerated reduction in lipoprotein secretion in the setting of apoB overexpression (since the MTP:apoB ratio would be even lower). To test this hypothesis, we examined the effects of heterozygous MTP deficiency on apoB metabolism in the setting of normal levels of apoB synthesis, half-normal levels of apoB synthesis (heterozygous Apob deficiency), and increased levels of apoB synthesis (transgenic overexpression of human apoB). Contrary to our expectations, half-normal levels of MTP reduced the plasma apoB100 levels to the same extent (ϳ25-35%) at each level of apoB synthesis. In addition, apoB secretion from primary hepatocytes was reduced to a comparable extent at each level of apoB synthesis. Thus, these results indicate that the concentration of MTP within the endoplasmic reticulum rather than the MTP:apoB ratio is the critical determinant of lipoprotein secretion. Finally, we found that heterozygosity for an apoB knockout mutation lowered plasma apoB100 levels more than heterozygosity for an MTP knockout allele. Consistent with that result, hepatic triglyceride accumulation was greater in heterozygous apoB knockout mice than in heterozygous MTP knockout mice.
Microsomal triglyceride transfer protein (MTP)
1 is expressed at high levels in the absorptive enterocytes of the intestine and hepatocytes, at moderate levels in the visceral endoderm of the yolk sac during embryonic development, and at relatively low levels in kidney and cardiac muscle (1) (2) (3) (4) . In each of these tissues, MTP plays a key role in the assembly and secretion of apoB-containing lipoproteins (1, 3, 5) . MTP is located within the lumen of the endoplasmic reticulum (ER) and is thought to transfer lipids to apoB as that molecule is translated, allowing apoB to assume a proper conformation for forming a spherical lipoprotein with a neutral lipid core (6) . In the absence of MTP, triglyceride-rich, apoB-containing lipoproteins cannot be assembled or secreted (3, 6, 7) . The mechanism of MTP action has attracted considerable scrutiny. Of note, several lines of evidence have suggested that the assembly of lipoproteins involves a direct interaction between MTP and apoB. First, Wu et al. (8) demonstrated that apoB can be immunoprecipitated from the microsomes of cultured hepatoblastoma cell lines with an antiserum against MTP. Second, the laboratory of Mahmood Hussain has provided biochemical evidence that MTP binds to apoB (9) and that this interaction depends on arginine and lysine residues within apoB (10) . Third, a pair of recent studies, each using independent experimental approaches, identified specific domains within the amino terminus of apoB that bind to the 97-kDa subunit of MTP (11, 12) . It has been suggested that apoB-MTP complexes could play an important role in the assembly of apoB-containing lipoproteins (12, 13) .
To define the role of MTP in lipoprotein assembly in vivo, our laboratory recently inactivated the mouse gene for the 97-kDa subunit of MTP (Mttp) (4) . Homozygous Mttp knockout mice died early in development, likely because an absence of lipoprotein secretion by the yolk sac interferes with the delivery of lipid nutrients to the developing mouse embryo (4, 14) . Heterozygous knockout mice developed normally and manifested a 50% reduction in MTP activity levels in both the liver and intestine. The half-normal MTP levels were accompanied by an ϳ25% reduction in plasma apoB100 levels on both chow and high fat diets.
The finding that half-normal levels of MTP appeared to reduce plasma apoB100 levels suggested that there is not a great excess of MTP within the ER of hepatocytes (4) . A key goal of the current study was to further elucidate that finding. In particular, we wanted to determine whether the effects of half-normal MTP levels in reducing lipoprotein levels would be equally noticeable at different levels of apoB expression. We imagined two possible scenarios by which half-normal levels of MTP might reduce the secretion of apoB-containing lipoproteins. One possibility was that the half-normal levels of MTP would reduce the ratio of MTP to apoB within the lumen of the ER, thereby reducing the number of direct protein-protein interactions between these molecules. If a normal ratio of MTP to apoB were critical for lipoprotein assembly, one might reasonably surmise that half-normal levels of MTP would have little effect on lipoprotein production in the setting of half-normal levels of apoB synthesis, since the MTP:apoB ratio would not be reduced below that in wild-type cells. According to this scenario, half-normal MTP levels might cause an even greater reduction in lipoprotein synthesis in the setting of increased levels of apoB synthesis, since the MTP:apoB ratio would be further reduced. A second possible scenario is that the ratio of MTP to apoB molecules is irrelevant and that the key consideration is simply the absolute concentration of MTP within the ER. If the absolute concentration of MTP were the most important factor, one would surmise that the consequences of halfnormal MTP levels would be independent of the apoB synthetic rate. We tended to favor the former scenario; thus, our a priori hypothesis was that the ratio of MTP to apoB would prove to be the critical factor governing lipoprotein production in the setting of half-normal MTP levels.
The fact that MTP and apoB bind to each other during lipoprotein assembly prompted us to consider another hypothesis. We hypothesized that overexpression of apoB might lead to more MTP-apoB interactions within the ER and that these more numerous MTP-apoB interactions might stabilize MTP, increasing its half-life within the ER. To the extent that this were the case, MTP levels in liver microsomes might be increased in the setting of high levels of apoB expression and decreased at low levels of apoB expression.
A key goal of this project was to address those two hypotheses: that the ratio of MTP to apoB might be the critical factor governing apoB production rates, and that changes in apoB expression might affect the levels of MTP activity within the liver. To address the latter hypothesis, we simply measured hepatic MTP activity levels in liver microsomes at three levels of apoB expression: low (heterozygosity for an Apob knockout mutation) (15) , normal (two wild-type Apob alleles), and high (two wild-type alleles plus a "high expressing" human APOB transgene) (16) . To assess the former hypothesis, that the ratio of MTP to apoB within the ER was a critical determinant of apoB production, we examined the phenotype of heterozygous Mttp knockout mice at each of the three distinct levels of apoB synthesis. For these studies, the metabolic effects of a single Mttp knockout allele were assessed with specific mouse apoB100 immunoassays and with metabolic labeling studies in primary mouse hepatocytes.
In addition to addressing these two hypotheses, we wanted to quantify and compare the effects of a mutant Apob allele and a mutant Mttp allele on hepatic lipoprotein secretion. This topic cannot be addressed convincingly with human investigations but can be addressed definitively in experiments with knockout mice.
MATERIALS AND METHODS
Genetically Modified Mice-Heterozygous Apob knockout mice (Apob ϩ/Ϫ ), heterozygous Mttp knockout mice (Mttp ϩ/Ϫ ), and high expressing hemizygous human APOB transgenic mice (HuBTg ϩ/o ) have been previously described (4, (15) (16) (17) . In high expressing human apoB transgenic mice on a chow diet, we have documented human apoB100 levels of ϳ40 -50 mg/dl (18) , and the total amount of apoB secretion from these cells is approximately twice as much as from wild-type mice (14) . The HuBTg ) and mice that were heterozygous for both the Apob and Mttp mutations (Apob ϩ/Ϫ Mttp ϩ/Ϫ ). We compared groups of mice with a single copy of an Mttp knockout allele with control mice with two normal Mttp alleles. For each of these comparisons, the control mice were invariably littermates. All mice were female and had a mixed genetic background (ϳ75% C57BL/6 and 25% 129/Sv). The mice were housed in a full-barrier facility and were fed a chow diet containing 4.5% fat (PicoLab Mouse Chow 20, No. 5058, Ralston Purina, St. Louis, MO). Blood was sampled for lipid and apolipoprotein measurements when the mice were greater than 2 months old. The mice sacrificed for measurement of liver triglyceride stores were more than 4 months old.
Lipid and Apolipoprotein Measurements-Plasma lipid levels were measured on fresh plasma samples (in duplicate) after a 4-h fast. Cholesterol levels were measured with the Abbott Spectrum kit (Abbott Laboratories Diagnostics Division, Abbott Park, IL), and triglyceride levels were determined with the triglyceride/GB kit (Roche Molecular Biochemicals) (19) . The plasma levels of mouse and human apoB100 were measured with monoclonal antibody-based radioimmunoassays (RIAs) (20, 21) .
Assessing the Distribution of Cholesterol within the Plasma Lipoproteins-The distribution of cholesterol within the plasma lipoproteins was assessed by size-fractionating 250 l of plasma (pooled from 7 female mice after a 4-h fast) by fast protein liquid chromatography (FPLC) on a Superose 6B 10/50 column (Amersham Pharmacia Biotech) (19) .
MTP Activity Assay and MTP Western Blots-Mouse livers were dissected and homogenized, and MTP activity levels were performed according to the procedures described by Wetterau et al. (1, 5) . For several groups of mice, the amount of the 97-kDa subunit of MTP was assessed on Western blots of sodium dodecyl sulfate-polyacrylamide gels using a rabbit antiserum against bovine MTP (provided by Dr. John Wetterau, Bristol-Myer Squibb, Princeton, NJ).
Metabolic Labeling of Primary Hepatocytes-Primary mouse hepatocytes were prepared and cultured as described previously (22) . The cells were allowed to attach for 90 min, and the medium was removed and replaced with fresh medium containing 50 l of [ 35 S]methionine/cysteine (Pro-mix, 530 Mbq/ml, Amersham Pharmacia Biotech) per ml of medium. After a 3-h incubation, a sample of the medium (40 l) was size-fractionated on a 4 -15% polyacrylamide-sodium dodecyl sulfate gel. The gel was dried, and the incorporation of 35 S into apoB48 and apoB100 was assessed with a Fuji Bio-Imaging Analyzer (Fiji Medical Systems, Stamford, CT). For each well of primary hepatocytes, the amount of 35 S incorporation into the apoB proteins was normalized to the amount of 35 S incorporation into characteristic triplet bands (secreted non-apoB proteins) that migrated immediately below the apoB48 band (see Fig. 4E below) .
Measurement of Liver Triglyceride Stores-Liver samples from each animal were disrupted with a homogenizer (Ultra-Turbax T8, VWR) for 2 min in 1.0 ml of a 2:1 mixture of chloroform and methanol. The homogenizer probe was rinsed twice with 1.0 ml of the same chloroform/ methanol mixture, bringing the total volume of the mixture to 3 ml. Next, 1.0 ml of water and 0.576 mg of tripentadecanoin (an internal standard dissolved in hexane) were added. After vortexing for 2 min, the sample was centrifuged for 10 min at 900 ϫ g. The bottom layer was transferred to a new tube and dried under a stream of nitrogen at 30°C. Each sample was resuspended in 40 l of hexane. The plate was sprayed with a fixative (10 mg of 8-hydroxy-1,3,6-pyrenetrisulfonic acid trisodium in 50 ml of methanol), and the triglyceride band was visualized with a hand-held UV lamp. The silica containing the triglycerides was scraped off and placed in a new tube and transmethylated with 1.0 ml of 3 N methanolic HCl. The samples were vortexed, incubated at room temperature overnight, and centrifuged for 3 min at 900 ϫ g. The liquid portion was transferred to a glass tube and dried under nitrogen. The samples were then resuspended in 1.0 ml of heptane, and the fatty acid methyl esters were quantified by gas chromatography (23) . After normalization of the data to the C-15 internal standard, triglyceride measurements were calculated as M of triglyceride/g of liver tissue.
Statistical Analysis-Mean levels of apoB, plasma lipids, or liver triglyceride stores are reported for each group of mice along with standard deviations or standard errors of the means. Statistical differences were modeled by analysis of variance with genotype being an intergroup factor.
RESULTS

MTP Activity and Protein Levels in Liver Extracts from Different Groups of Mice-
We found that hepatic MTP activity levels were 49.7% lower in Mttp ϩ/Ϫ mice than in wild-type mice (p Ͻ 0.001) (Fig. 1A) . Recent studies have suggested that apoB and MTP bind to each other during lipoprotein assembly (8, 11, 12) . We hypothesized that overexpression of human apoB might conceivably lead to an increased number of those interactions, potentially stabilizing MTP within the ER and leading to increased amounts of MTP activity in hepatic microsomes. Our data, however, did not support this hypothesis. The hepatic MTP activity levels were no higher in HuBTg ϩ/o mice than in wild-type mice and were 50% lower in HuBTg ϩ/o Mttp ϩ/Ϫ mice than in HuBTg ϩ/o mice (p Ͻ 0.001) (Fig. 1A) . A single copy of an Apob knockout allele had no significant effect on hepatic MTP activity levels (Fig. 1A) . As judged by Western blots, the half-normal MTP activity levels in heterozygous Mttp knockout mice were due to half-normal levels of the 97-kDa subunit of MTP (Fig. 1B) . Fig. 2A-C) . These studies suggested that the Mttp knockout mutation reduced mouse apoB100 levels to a similar extent at each level of apoB synthesis. To further test this idea, we measured plasma apoB100 levels for each mouse in each of the six groups (Table I) . Three features of those data are noteworthy. First, the Mttp knockout allele reduced plasma apoB100 levels to a similar extent at each level of apoB synthesis (ϳ25-35%). The effect of half-normal MTP activity levels on apoB100 levels was neither diminished at reduced levels of apoB synthesis nor exaggerated by increased levels of apoB expression. Second, the Apob knockout allele reduced plasma apoB levels far more (Ͼ50%) than the Mttp knockout allele (ϳ25%). Third, human APOB expression increased the plasma levels of mouse apoB100. Increased plasma levels of mouse apoB100 in the setting of human apoB overexpression were not unexpected, as we had encountered the same finding in a recent study of atherogenesis in human apoB transgenic mice (24) .
Decreased Plasma ApoB100 and Lipid Levels in Mttp
We also assessed the effects of the Mttp knockout mutation on the plasma levels of human apoB100 in HuBTg ϩ/o and HuBTg ϩ/o Mttp ϩ/Ϫ mice. As shown in Table I and Fig. 2, B and D, the defective Mttp allele resulted in very similar reductions in the levels of mouse and human apoB100 (29 and 32%, respectively).
Measurements of total plasma cholesterol or triglycerides were poor surrogates for the apoB100 measurements, at least from the perspective of identifying metabolic perturbations resulting from half-normal MTP activity levels. Inactivating one of the two Mttp alleles had no effect on plasma triglyceride levels. The total plasma cholesterol level was significantly lower in Mttp ϩ/Ϫ mice than in the wild-type mice, but no significant effect on cholesterol levels was noted in the setting of the human apoB transgene or the Apob knockout mutation ( Table II) . The FPLC studies revealed that a single copy of the Mttp mutation reduced the levels of cholesterol in the intermediate and low density lipoproteins by ϳ20% at each level of apoB synthesis (Fig. 3) . However, on a chow diet, the quantitative significance of this reduction was modest and in some cases was offset by increases in high density lipoprotein cholesterol levels.
Decreased ApoB Secretion in the Setting of a Single Mttp Knockout Allele-To investigate the mechanism for the reduced plasma apoB levels in the setting of half-normal levels of MTP, we performed metabolic labeling experiments on the primary hepatocytes of different groups of mice (Fig. 4) . The amount of apoB100 in the medium from Mttp ϩ/Ϫ hepatocytes was 27% lower than in wild-type mice (p ϭ 0.026 and 0.037 in two independent experiments) (Fig. 4, A and B) . The Mttp mutation lowered apoB100 secretion by 28% in the setting of the human apoB transgene (p ϭ 0.002 and 0.015 in two experiments) and by 21% in the setting of an Apob knockout allele (p ϭ 0.016 and 0.014 in two experiments) (Fig. 4, A and B) . The effect of the Mttp mutation on apoB48 secretion was modest. ApoB48 secretion from Mttp ϩ/Ϫ hepatocytes was 15% lower than from wildtype hepatocytes (p ϭ 0.125 and 0.048 in two experiments) (Fig.  4, C and D) . The Mttp mutation lowered apoB48 secretion by 18% (p ϭ 0.036 and 0.049 in two experiments) in the setting of the human apoB transgene and by 15% in the setting of an Apob knockout allele (p ϭ 0.027 and 0.034 in two experiments) (Fig. 4, C and D) . Fig. 4E shows an determined whether the reduced apoB secretion in the setting of the Mttp and Apob mutations would be accompanied by an accumulation of triglycerides within the liver. Pairwise comparisons of littermates revealed a tendency for higher liver triglyceride stores in the setting of the Mttp mutation, but none of these differences achieved statistical significance (Fig. 5) . Interestingly, the hepatic triglyceride stores were greater in heterozygous Apob knockout mice than in heterozygous Mttp knockout mice (Fig. 5) .
DISCUSSION
In our initial characterization of Mttp knockout mice (4), we noted that the Mttp ϩ/Ϫ mice displayed half-normal MTP activity levels and an ϳ25% reduction in plasma apoB100 levels. The latter finding was somewhat surprising, given the prevailing view that heterozygosity for MTP deficiency in humans has no effect on plasma lipid or lipoprotein profiles (25, 26) .
In the current study, we hypothesized that the ratio of MTP to apoB might be a key determinant of lipoprotein secretion. Thus, we suspected that half-normal MTP levels might have little effect on lipoprotein production when apoB synthesis was also reduced by 50% (since the ratio of MTP to apoB within the ER would not be abnormally low) and might have an exaggerated effect in the setting of apoB overexpression (since the ratio of MTP to apoB would be further reduced). We further hypothesized that increased levels of apoB synthesis could affect the stability of the MTP protein and, hence, the amount of MTP activity in liver microsomes. Each of these two hypotheses seemed plausible in view of evidence indicating the existence of a direct MTP-apoB interaction within the ER (8, 9, 11, 12) and suggestions that an MTP-apoB complex might play a key role in lipoprotein assembly (12, 13) . Our data, however, provided no support for either hypothesis. Hepatic MTP activity levels were completely unaffected by either apoB overexpression (a human APOB transgene) or by apoB underexpression (heterozygosity for an Apob knockout mutation). Also, half-normal levels of MTP reduced apoB100 production rates to a similar extent at each level of apoB synthesis.
To the best of our knowledge, this is the only study to quantify the relative impact of half-normal levels of MTP and apoB on lipoprotein assembly and secretion. Our experiments revealed that both mutations reduced hepatic lipoprotein secretion, but the effect of the Apob mutation was much greater. Of course, this conclusion should not be generalized past the specific experimental model that we examined. We examined hepatic secretion in animals fed a chow diet, and no conclusions can or should be drawn regarding the relative importance of these two gene products on intestinal lipoprotein secretion or on hepatic lipoprotein secretion in the setting of a high fat diet.
The fact that the effects of half-normal MTP levels were similar at each level of apoB synthesis indicates that the absolute ratio of MTP to apoB is not an important determinant of lipoprotein secretion, at least within the range of apoB synthesis rates that we examined. Instead, it appears that the most important factor is the absolute amount or concentration of MTP within the ER. We emphasize that our experiments did not attempt to study MTP-apoB interactions directly nor do the results of our experiments necessarily cast doubt on the potential importance of these direct interactions during lipoprotein assembly. Our data simply show that half-normal levels of MTP influence lipoprotein secretion similarly at different levels of apoB synthesis.
MTP is not the only factor that can affect lipoprotein production. Our findings with the Apob knockout mice reveal that reduced amounts of apoB synthesis can also limit hepatic lipoprotein production. Other investigations have documented that the levels and intracellular availability of lipids can limit cellular lipoprotein secretion (27) (28) (29) (30) (31) (32) . Thus, lipoprotein assembly and secretion require adequate levels of apoB, MTP, and lipids, and reductions in any one of these can limit the output of lipoproteins from cells. Reductions in two of these factors can result in additive decreases in lipoprotein production, as demonstrated in the current studies by the low plasma apoB100 levels and low apoB100 production rates in Apob ϩ/Ϫ Mttp ϩ/Ϫ mice.
In this study, we relied mainly on apoB metabolic labeling studies and monoclonal antibody-based apoB RIAs to investigate the metabolic effects of half-normal MTP activity levels. Both of these strategies revealed reproducible and concordant effects of the Mttp knockout mutation on apoB metabolism. It is interesting that the plasma lipid levels were poor surrogates for the apoB measurements. The total plasma cholesterol levels were quite insensitive to the effects of the Mttp knockout mutation, although the FPLC fractionation studies did uncover ϳ20% reductions in low density lipoprotein cholesterol levels at each level of apoB synthesis. A single copy of the Mttp knockout allele had no detectable effect on plasma triglyceride levels, a somewhat surprising result in light of recent studies that have shown that hepatic MTP plays a crucial role in triglyceride secretion (7, 33) . We do not understand why the Mttp mutation failed to reduce the plasma triglyceride levels. It seems possible that the variability in plasma triglyceride levels made it difficult to identify such an effect or perhaps that changes in the activity of triglyceride removal pathways masked any changes in hepatic triglyceride secretion rates. The metabolic labeling studies revealed that half-normal MTP levels reduced apoB100 secretion more than they reduced apoB48 secretion. This result is consistent with recent findings with MTP inhibitor compounds in cultured cells (29, 34 -36) and also with recent findings from liver-specific Mttp knockout mice (7). We used Cre/loxP recombination techniques to produce liver-specific Mttp knockout mice and documented a Ͼ95% reduction in both hepatic MTP activity levels and plasma apoB100 levels (7). Interestingly, the effects of the liver-specific knockout on plasma apoB48 levels were modest, and primary hepatocytes from those mice secreted substantial amounts of the apoB48 protein.
In this study, a defective Apob allele was more potent in reducing plasma apoB levels than a defective Mttp allele. Equally intriguing, however, were the relative effects of the Mttp and Apob mutations on hepatic stores of triglycerides. Given the obligatory role of MTP in the entry of triglycerides into the secretory organelles of hepatocytes (7), one might have reasonably hypothesized that half-normal MTP levels would significantly increase liver triglyceride stores. Moreover, it would have been reasonable to hypothesize that the normal MTP activity levels in Apob ϩ/Ϫ mice would completely prevent an accumulation of triglycerides in the liver simply by packing each nascent apoB-containing lipoprotein with a double dose of triglycerides. Our current data appear to be inconsistent with both of these hypotheses. Liver triglyceride stores were increased only modestly by the Mttp mutation, and the increase was not statistically significant. In addition, the Apob mutation appeared to have a much greater effect on liver triglyceride stores than the Mttp mutation, just as the Apob mutation had a greater effect in reducing the secretion of apoB-containing lipoproteins. These findings, as far as we are aware, are novel, as there have been no prior studies of the effects of heterozygous apoB or MTP deficiency on hepatic triglyceride stores in either mice or humans.
The results of our current experiments, that a 50% reduction in MTP levels reduces plasma lipoprotein levels with only a modest effect on liver triglyceride stores, will likely be heartening to pharmaceutical company investigators who are developing MTP inhibitor drugs to treat human hyperlipidemias. Although the safety profile of these drugs in humans remains to be established, a study of an MTP inhibitor drug in rabbits and hamsters was recently reported (37) . The MTP inhibitor compound reduced plasma lipoprotein levels while increasing liver triglyceride stores only modestly. Those results appeared to be consistent with our genetic studies.
The finding of increased triglyceride stores in the Apob ϩ/Ϫ mice should also be of interest to the pharmaceutical industry, particularly to investigators who are seeking new therapeutic strategies for treating hyperlipidemias. Our results suggest that pharmaceutical strategies designed to reduce the transcription of the apoB gene or any other strategy to reduce the number of apoB transcripts may not be free of the hepatic steatosis issue. The issue of increased triglyceride stores may be shared by any strategy that reduces the secretion of apoBcontaining lipoproteins.
